TTrialPathMatch Me to Trials
← Back to trials
RecruitingObsessive-Compulsive Disorder

Safety and Efficacy of Pramipexole Treatment in Resistant Obsessive-Compulsive Disorder (OCD)

Eligible age

18–64 yrs

Accepts

All genders

Locations

0 states

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

The most common and effective treatment for OCD is pharmacological therapy that includes selective serotonin reuptake inhibitors (SSRIs) antidepressants and, in the case of patients resistant to this approach, a combination with antipsychotics. Risperidone and aripiprazole are atypical antipsychotics that act on dopamine (D2) and serotonin receptors. Studies have shown that these drugs are effective in boosting SSRIs for the treatment of OCD in resistant patients. Currently a high percentage of people diagnosed with OCD do not respond to the existing treatments. Pramipexole is a dopaminergic receptor agonist that specifically binds to dopamine D2 and D3 receptors, having demonstrated benefit in resistant depression. The aim of this clinical trial is to explore how pramipexole can act in the treatment of OCD in resistant patients, evaluating its safety and efficacy.

Sponsor: Clinical Academic Center (2CA-Braga)

You may qualify if…

  • ✓ 1. Age between 18 and 64 years;
  • ✓ 2. European Portuguese as mother tongue;
  • ✓ 3. Patients diagnosed with OCD, regardless of subtype, according to DSM-5 and/or ICD-10 criteria;
  • ✓ 4. Yale-Brown Obsessive Compulsive Scale (Y-BOCS) score ≥ 16;
  • ✓ 5. Patients resistant to the first-line treatment for OCD:
  • ✓ 5.1 Patients who do not respond to treatment with at least two selective serotonin reuptake inhibitor antidepressants (SSRIs) at the maximum tolerated therapeutic dose during at least 12 weeks, i.e. patients in whom there is no reduction in the Y-BOCS score by 25% relative to the score obtained before starting treatment with SSRIs.
  • ✓ 5.2 Patients who do not respond to treatment with risperidone or aripiprazole as potentiation of the SSRIs at the maximum tolerated therapeutic dose during at least 12 weeks, i.e. patients in whom there is no reduction in the Y-BOCS score by 25% relative to the score obtained before starting treatment with the antipsychotic or patients in whom the Y-BOCS score is kept ≥ 16 after the treatment with the antipsychotic.

You may not qualify if…

  • ✕ 1. Patients with current or anterior history of psychotic illness (schizophrenia, delusions, among others);
  • ✕ 2. Patients with bipolar disorder;
  • ✕ 3. Patients with tick disorder;
  • ✕ 4. Patients with borderline personality disorder;
  • ✕ 5. Patients with social anxiety disorder;
  • ✕ 6. Patients with current or anterior history of dietary behavior disorders (at least in the last 6 months);
  • ✕ 7. Patients with a history of neurological disease or traumatic brain injury;
  • ✕ 8. Patients with history of alcohol abuse or illicit substances (at least in the last 6 months);

Source: ClinicalTrials.gov · NCT06611592 · last updated 2025-01-06